← Browse by Condition
Medical Condition

advanced solid tumors

Total Trials
36
Recruiting Now
36
Trial Phases
EARLY_Phase 1, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumors Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumors?
ClinicalMetric currently tracks 36 actively recruiting clinical trials for advanced solid tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 36. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumors?
advanced solid tumors research spans Phase 1 (30 trials), Phase 2 (12 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumors clinical trial?
Eligibility criteria for advanced solid tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
30
Phase 2
12
Top Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd. 2 trials
Anhui Provincial Hospital 1 trial
TCRx Therapeutics Co.Ltd 1 trial
Beijing Konruns Pharmaceutical Co., Ltd. 1 trial
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT07106814 EARLY_Phase 1
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Enrollment
36 pts
Location
China
Sponsor
Anhui Provincial Hospital
View Trial →
NCT07596693 Phase 1
Recruiting
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
Enrollment
30 pts
Location
China
Sponsor
TCRx Therapeutics Co.Ltd
View Trial →
NCT04387916 Phase 1
Recruiting
A Study of KC1036 in Patients with Advanced Solid Tumors
Enrollment
207 pts
Location
China
Sponsor
Beijing Konruns Pharmaceutical...
View Trial →
NCT07241936 Phase 1, Phase 2
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Enrollment
444 pts
Location
China
Sponsor
CSPC ZhongQi Pharmaceutical Te...
View Trial →
NCT06384352 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Enrollment
155 pts
Location
United States, Austr...
Sponsor
MediLink Therapeutics (Suzhou)...
View Trial →
NCT05541822 Phase 2
Recruiting
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Enrollment
178 pts
Location
United States, South...
Sponsor
Abion Inc
View Trial →
NCT06329206 Phase 1
Recruiting
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Enrollment
156 pts
Location
China
Sponsor
Suzhou Genhouse Bio Co., Ltd.
View Trial →
NCT06400485 EARLY_Phase 1
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
Enrollment
24 pts
Location
American Samoa, Aust...
Sponsor
Multitude Therapeutics Inc.
View Trial →
NCT04626635 Phase 1, Phase 2
Recruiting
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Enrollment
933 pts
Location
United States, Franc...
Sponsor
Regeneron Pharmaceuticals
View Trial →
NCT06801470 Phase 1
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
Enrollment
137 pts
Location
China
Sponsor
CD (Suzhou) Biopharma Co., Ltd...
View Trial →
NCT06915753 Phase 1
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Enrollment
100 pts
Location
United States, Canad...
Sponsor
Tyra Biosciences, Inc
View Trial →
NCT06770569 Phase 1
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Enrollment
100 pts
Location
Australia, China
Sponsor
Shandong Suncadia Medicine Co....
View Trial →
NCT06314373 Phase 1, Phase 2
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
Enrollment
243 pts
Location
China
Sponsor
Xizang Haisco Pharmaceutical C...
View Trial →
NCT06835569 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Enrollment
448 pts
Location
United States
Sponsor
Alterome Therapeutics, Inc.
View Trial →
NCT07321574 Phase 2
Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Enrollment
110 pts
Location
China
Sponsor
Shanghai AB PharmaTech Ltd.
View Trial →
NCT07231458 Phase 1
Recruiting
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Enrollment
27 pts
Location
Germany, Spain
Sponsor
Abalos Therapeutics GmbH
View Trial →
NCT07164950
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
Enrollment
58 pts
Location
China
Sponsor
Sheng Zhang
View Trial →
NCT07589530 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Beijing Biotech
View Trial →
NCT06990464 Phase 1
Recruiting
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Enrollment
156 pts
Location
China
Sponsor
Shanghai Institute Of Biologic...
View Trial →
NCT06760819 Phase 2
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Enrollment
111 pts
Location
United States, Austr...
Sponsor
Bayer
View Trial →
NCT07042100 Phase 1
Recruiting
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Enrollment
177 pts
Location
United States, Austr...
Sponsor
Sun Pharma Advanced Research C...
View Trial →
NCT05881525 Phase 1
Recruiting
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
TCRCure Biopharma Ltd.
View Trial →
NCT06795815
Recruiting
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
Enrollment
75 pts
Location
Italy
Sponsor
Azienda USL Reggio Emilia - IR...
View Trial →
NCT07561437 EARLY_Phase 1
Recruiting
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Enrollment
18 pts
Location
China
Sponsor
Base Therapeutics (Shanghai) C...
View Trial →
NCT06299839 Phase 1
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
Enrollment
48 pts
Location
United States, Bulga...
Sponsor
Pasithea Therapeutics Corp.
View Trial →
NCT06605222 Phase 1, Phase 2
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Enrollment
201 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT06532565 Phase 1
Recruiting
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Enrollment
154 pts
Location
United States, Canad...
Sponsor
Gilead Sciences
View Trial →
NCT06943820 Phase 1, Phase 2
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
Enrollment
230 pts
Location
China
Sponsor
Akeso
View Trial →
NCT06907628 Phase 1
Recruiting
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Enrollment
150 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06993844 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Enrollment
233 pts
Location
United States, China
Sponsor
Ensem Therapeutics
View Trial →
NCT06895928 Phase 2
Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Enrollment
400 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT07539285 Phase 1
Recruiting
A Study of HDM2024 in Participants With Advanced Solid Tumors
Enrollment
63 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar...
View Trial →
NCT06224855 Phase 1
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Enrollment
280 pts
Location
China
Sponsor
Hangzhou DAC Biotechnology Co....
View Trial →
NCT06178614 Phase 1
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
Enrollment
200 pts
Location
United States, Franc...
Sponsor
Janssen Research & Development...
View Trial →
NCT07328217 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Enrollment
203 pts
Location
China
Sponsor
Dizal Pharmaceuticals
View Trial →
NCT04222413 Phase 1
Recruiting
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Enrollment
116 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →

Related Conditions

advanced breast cancer (2) metastatic hepatocellular carcinoma (1) solid tumors (1) solid tumor adult (1) fgfr gene amplification (1) fgfr gene alterations (1) fgfr3 gene alteration (1) fgfr3 gene mutation (1) fgfr4 gene mutation (1) fgfr4 gene fusions (1) fgf19 gene amplification (1) fgf19 gene overexpression (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology